Crinetics Pharmaceuticals, INC Form 4 insider transactions

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold 14,375 shares of common stock after exercising stock options at a lower price.

Crinetics Pharmaceuticals' CEO, Richard Scott Struthers, exercised stock options and reported changes in his beneficial ownership of company stock.

Crinetics Pharmaceuticals CEO Richard Scott Struthers exercised stock options and sold shares on April 4, 2024, according to a recent SEC Form 4 filing.

Director Stephanie Okey exercised stock options and sold shares of Crinetics Pharmaceuticals on March 28, 2024.

Crinetics Pharmaceuticals' Chief Operating Officer, Jeff E. Knight, exercised stock options and sold shares in the open market on March 22, 2024.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on March 20, 2024.

Director Matthew K. Fust of Crinetics Pharmaceuticals exercised stock options and sold shares on March 20, 2024, according to a Form 4 filing with the SEC.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, sold shares to cover tax obligations related to vesting restricted stock units.

Jeff E. Knight, COO of Crinetics Pharmaceuticals, disposed of 4,283 shares of common stock on March 18, 2024, to cover tax obligations related to vesting Restricted Stock Units.

James Hassard, Chief Commercial Officer of Crinetics Pharmaceuticals, reports disposition of shares to cover tax obligations upon vesting of Restricted Stock Units.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports the withholding of 3,655 common stock shares to cover tax obligations upon vesting of Restricted Stock Units.

CFO Marc Wilson reports the disposition and sale of Crinetics Pharmaceuticals (CRNX) common stock related to tax obligations and a pre-arranged trading plan.

Richard Scott Struthers, President & CEO of Crinetics Pharmaceuticals, reports the disposal of shares to cover tax obligations related to vesting Restricted Stock Units.

Chief Commercial Officer James Hassard reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

CFO of Crinetics Pharmaceuticals, Marc Wilson, reports the acquisition of 25,500 restricted stock units and 95,500 stock options.

Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reports acquisition of shares and stock options, signaling potential confidence in the company's future.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, acquired shares and options in the company on March 4, 2024.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports acquisition of shares and stock options.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports the acquisition of 23,000 shares of common stock and options to purchase 87,000 shares.